New Board Member Brings More Expertise to AIkido Pharma
NEW YORK, April 26, 2021 / PRNewswire / – AIkido Pharma Inc. (Nasdaq: AIKI) (“AIkido” or the “Company”) today announced that Dr. Matthew frieman joined the Scientific Council of the Company.
“Dr. Frieman is a World class scientist and inventor. His research is truly cutting edge and his work advances science in this extremely important area. field,” commented Mr. Anthony hayes, CEO of Akido. “We are honored to have him join our team of advisors and to work more directly in our efforts to advance the development of his technology, which we had previously licensed. The coronavirus is still a notable problem that continues to impact society and we are very proud of it. supporting the work of Dr Frieman. “
Dr Frieman is Associate Professor in the Department of Microbiology and Immunology at University of Maryland School of Medicine and an internationally renowned virologist with expertise in coronaviruses for which he has been studying since 2004. More specifically, he specializes in highly pathogenic coronaviruses which include the severe acute respiratory syndrome coronavirus (SARS-CoV) which appeared in 2003, Middle East respiratory syndrome coronavirus (MERS-CoV) which appeared in 2012 and SARS-CoV-2, which appeared in 2019.
Dr. Frieman’s research interests range from basic science to translating these findings into human therapies. His work on coronavirus replication stems from his interest in studying how the virus interacts with cellular machinery during infection. He identified proteins encoded for SARS-CoV-1 and MERS-CoV that alter the host’s response to infection, including proteins that block the innate immune response to allow the virus to replicate silently without only the cell detects that a virus was there. Some of these viral proteins inhibit the induction and signaling of interferon while others reverse cellular proteins that hold coronaviruses on the cell surface. These findings were also used by Dr Frieman to identify cellular proteins that interact with the proteins of the coronavirus to try to block these actions. He is currently developing new compounds that target host proteins so that they can thwart the pro-viral function of coronavirus proteins. He has shown that this cellular target, the SKI complex, plays a role in many viruses, so the new compounds he identified inhibit SARS-CoV, SARS-CoV-2, influenza virus, Ebolavirus virus and Marburg virus. This work continues to identify more potent inhibitors of this complex for use in animal models and possibly humans.
About Akido Pharma Inc.
AIkido Pharma Inc. was originally established in 1967 and is a biotechnology company with a diverse portfolio of small molecule cancer therapies. The company’s platform consists of patented technology from leading universities and researchers, and we are currently developing an innovative therapeutic drug platform through strong partnerships with educational institutions. world-renowned, including the University of Texas in Austin and the University of Maryland at Baltimore. Our diverse portfolio of therapeutic products includes therapies for pancreatic cancer and prostate cancer. We are constantly looking to expand our pipeline to address unmet medical needs in oncology. The Company is also developing a broad-spectrum antiviral platform that could potentially inhibit the replication of several viruses, including influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus. .
Certain statements contained in this press release constitute “forward-looking statements” within the meaning of federal securities laws. Words such as “may”, “could”, “will”, “should”, “believe”, “expect”, “anticipate”, “estimate”, “continue”, “predict”, “foresee”, “plan”, “plan”, “intention” or similar expressions, or statements regarding current intention, belief or expectations, are forward-looking statements. Although the Company believes that these forward-looking statements are reasonable, we should not place undue reliance on these forward-looking statements, which are based on information available to us as of the date of this press release. These forward-looking statements are based on current estimates and assumptions and are subject to various risks and uncertainties, including, without limitation, those set forth in the Company’s filings with the SEC, without being limited to factors of risk related to its activities contained therein. Thus, the actual results could be materially different. The Company expressly disclaims any obligation to update or modify statements whether as a result of new information, future events or otherwise, except as required by law.
Brett maas, Management partner
Telephone: (646) 536-7331
Email: [email protected]
AIkido Pharma Inc .:
Email: [email protected]
View original content to download multimedia: http: //www.prnewswire.com/news-releases/aikido-pharma-announces-inventor-and-scientist-dr-matthew-frieman-joins-scientific-advisory-board-301276722 .html
SOURCE AIkido Pharma Inc.